Abeona Therapeutics Statistics
Total Valuation
ABEO has a market cap or net worth of $254.59 million. The enterprise value is $164.07 million.
Important Dates
The last earnings date was Thursday, November 14, 2024, before market open.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ABEO has 43.59 million shares outstanding. The number of shares has increased by 93.20% in one year.
| Current Share Class | 43.59M |
| Shares Outstanding | 43.59M |
| Shares Change (YoY) | +93.20% |
| Shares Change (QoQ) | -6.14% |
| Owned by Insiders (%) | 5.10% |
| Owned by Institutions (%) | 42.55% |
| Float | 28.70M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 56.49 |
| PB Ratio | 5.45 |
| P/TBV Ratio | 5.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.12, with a Debt / Equity ratio of 0.50.
| Current Ratio | 6.12 |
| Quick Ratio | 6.04 |
| Debt / Equity | 0.50 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -18.78 |
Financial Efficiency
Return on equity (ROE) is -209.50% and return on invested capital (ROIC) is -78.60%.
| Return on Equity (ROE) | -209.50% |
| Return on Assets (ROA) | -40.68% |
| Return on Capital (ROIC) | -78.60% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$845,619 |
| Employee Count | 84 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +37.23% in the last 52 weeks. The beta is 1.50, so ABEO's price volatility has been higher than the market average.
| Beta (5Y) | 1.50 |
| 52-Week Price Change | +37.23% |
| 50-Day Moving Average | 6.19 |
| 200-Day Moving Average | 5.76 |
| Relative Strength Index (RSI) | 36.36 |
| Average Volume (20 Days) | 332,848 |
Short Selling Information
The latest short interest is 2.64 million, so 6.05% of the outstanding shares have been sold short.
| Short Interest | 2.64M |
| Short Previous Month | 2.77M |
| Short % of Shares Out | 6.05% |
| Short % of Float | 9.19% |
| Short Ratio (days to cover) | 10.79 |
Income Statement
| Revenue | n/a |
| Gross Profit | -23.54M |
| Operating Income | -60.75M |
| Pretax Income | -76.66M |
| Net Income | -71.03M |
| EBITDA | -58.79M |
| EBIT | -60.75M |
| Earnings Per Share (EPS) | -$2.01 |
Full Income StatementBalance Sheet
The company has $109.70 million in cash and $23.11 million in debt, giving a net cash position of $86.59 million or $1.99 per share.
| Cash & Cash Equivalents | 109.70M |
| Total Debt | 23.11M |
| Net Cash | 86.59M |
| Net Cash Per Share | $1.99 |
| Equity (Book Value) | 45.77M |
| Book Value Per Share | 1.05 |
| Working Capital | 94.24M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$48.69 million and capital expenditures -$1.88 million, giving a free cash flow of -$50.57 million.
| Operating Cash Flow | -48.69M |
| Capital Expenditures | -1.88M |
| Free Cash Flow | -50.57M |
| FCF Per Share | -$1.16 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -1,155.34% |